Twenty four patients were studied prior to and after 6 and 12 weeks therapy with isotretinoin (17 patients) for acne and related disorders, or with etretinate (7 patients) for psoriasis and related disorders. Patients treated with isotretinoin had a significant reduction in natural killer cell activity at an effector: target cell ratio of 100: 1 at 12 weeks and also a reduction in natural killer cell numbers at this time. Patients treated with etretinate had elevated natural killer cell activity and a significant elevation of natural killer cell numbers at 12 weeks. Other tests which were performed and showed no significant change at 6 or 12 weeks compared with starting levels included lymphocyte transformation in response to phytohaemagglutinin, pokeweed mitogen and concanavalin A, total numbers of circulating T lymphocytes, B lymphocytes and T helper and T suppressor subsets, numbers of epidermal Langerhans cells and serum levels of IgA, IgM and IgE. In view of the involvement of natural killer cells in the initial phase of organ rejection, these results suggest that isotretinoin is the safer of the two retinoids if administration to renal transplant recipients is considered, particularly in the immediate post-transplant period.
This study was designed to detect possible changes in the immunocytology of the human immune system in the skin, cervix and peripheral blood of patients with chronic renal failure (CRF) treated by conservative methods, haemodialysis (HD) and continuous ambulatory peritoneal dialysis (CAPD). In the skin, Langerhans cell numbers were reduced in CRF, CAPD and HD patients but in the cervix, Langerhans cells were reduced only in the CRF patients. There was a preponderance of T suppressor lymphocytes compared with T helper lymphocytes in the epidermis in the CRF and the CAPD groups. The presence of natural killer cells in the epidermis of the renal groups compared to controls was significant in the CRF and HD patients while the presence of T suppressor lymphocytes in the epidermis compared to controls was significant only in the CAPD patients. In the dermis, there was a mixed cellular infiltrate of T helper and T suppressor lymphocytes but with no subset attaining significance. The dermal infiltrate of T helper lymphocytes in all three groups of renal patients was significantly reduced compared to controls. In CRF patients, peripheral blood pan T cells, T helper and T suppressor lymphocytes and B lymphocytes were reduced, while T suppressor lymphocytes were reduced in both HD and CAPD patients, compared to controls. Though the results confirm alteration of the immunocytology of the skin, cervix and peripheral blood, we could not relate them to a clinical finding.
Continuous ambulatory peritoneal dialysis (CAPD) is being increasingly used to treat chronic renal failure in New Zealand. Peritonitis due in particular to gram positive organisms remains the major complication. Three of 92 CAPD patients trained in the Wellington Renal Unit had tuberculous peritonitis, a previously rarely reported complication. Gram positive or Gram negative bacterial infections preceded or followed isolation of Mycobacterium tuberculosis. Differential peritoneal fluid leucocyte counts were not predictive of tuberculous infection and total leucocyte counts remained elevated in tuberculous patients treated for other concurrent bacterial peritonitides. Systemic toxicity was not encountered in these patients, symptoms being confined almost entirely to the peritoneum. CAPD was continued during treatment with anti-tuberculous therapy, in all three patients. However, peritoneal pain on dialysis fluid in-flow necessitated temporary hemodialysis management in two. Anti-tuberculous chemoprophylaxis may be prudent in the at-risk Polynesian patient with chronic renal failure who is being considered for CAPD management.
Itraconazole is as an anti-fungal agent with the ability to inhibit the Hedgehog signalling pathway, which makes it a candidate drug that can be repurposed for the treatment of basal cell carcinomas (BCCs). We present a case of metastatic BCC, treated with oral itraconazole 100 mg twice daily, that resulted in sustained partial regression of metastatic pulmonary nodules. A systematic review on the clinical outcomes of BCCs treated with itraconazole highlights that current evidence for its clinical application remains limited and that this is the first case report where itraconazole monotherapy has achieved favourable response in metastatic BCC.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.